Baroreflex Amplification and Carotid Body Modulation for the Treatment of Resistant Hypertension

Overview

Journal Curr Hypertens Rep

Specialty Cardiology & Vascular Diseases

Date 2020 Mar 14

PMID 32166464

Citations 10

Authors

Eline H Groenland

Wilko Spiering

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Patients with true resistant hypertension (RH) are characterized by having high sympathetic activity and therefore potentially benefit from treatments such as baroreflex amplification (baroreflex activation therapy (BAT) or endovascular baroreflex amplification therapy (EVBA)) or carotid body (CB) modulation. This review aims at providing an up-to-date overview of the available evidence regarding these two therapies.

Recent Findings: In recent years, increasing evidence has confirmed the potential of baroreflex amplification, either electrically (Barostim neo) or mechanically (MobiusHD), to improve blood pressure control on short- and long-term with only few side effects, in patients with RH. Two studies regarding unilateral CB resection did not show a significant change in blood pressure. Only limited studies regarding CB modulation showed promising results for transvenous CB ablation, but not for unilateral CB resection. Despite promising results from mostly uncontrolled studies, more evidence regarding the safety and efficacy from ongoing large randomized sham-controlled trials is needed before baroreflex amplification and CB modulation can be implemented in routine clinical practice.

Citing Articles

Sub-Chronic Peroneal Nerve Stimulation Lowers Ambulatory Blood Pressure in Spontaneously Hypertensive Rats.

Romero K, Gonzalez-Gonzalez M, Lloyd D, Nguyen K, Eli N, Akay Y IEEE Open J Eng Med Biol. 2024; 6:140-146.

PMID: 39698123 PMC: 11655098. DOI: 10.1109/OJEMB.2024.3477411.

A Review of the Risk Factors and Management of Refractory Hypertension: The Role of Carotid Sinus Stimulation and Renal Nerve Denervation.

Nwosu I, Oladiran O, Rivera M, Oladiran O, Nwosu A, Dim C J Community Hosp Intern Med Perspect. 2024; 14(4):18-24.

PMID: 39391106 PMC: 11464058. DOI: 10.55729/2000-9666.1364.

Beyond Conventional Control: Insights Into Drug-Resistant Hypertension.

Chhabra P, Dutta R, Sahu P, Joshi A Cureus. 2023; 15(8):e43617.

PMID: 37719515 PMC: 10503878. DOI: 10.7759/cureus.43617.

Hypertension in chronic kidney disease: What lies behind the scene.

Ameer O Front Pharmacol. 2022; 13:949260.

PMID: 36304157 PMC: 9592701. DOI: 10.3389/fphar.2022.949260.

A system of real-time neural recording and stimulation and its potential application in blood pressure modulation.

Shen A, Li R, Li Y, Guo J, Wang J, Sui X Front Med Technol. 2022; 4:941686.

PMID: 36035774 PMC: 9399767. DOI: 10.3389/fmedt.2022.941686.

References

Bisognano J, Bakris G, Nadim M, Sanchez L, Kroon A, Schafer J . Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011; 58(7):765-73. DOI: 10.1016/j.jacc.2011.06.008. View

Achelrod D, Wenzel U, Frey S . Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2014; 28(3):355-61. DOI: 10.1093/ajh/hpu151. View

ROTHFELD E, Parsonnet V, Raman K, ZUCKER I, Tiu R . The effect of carotid sinus nerve stimulation on cardiovascular dynamics in man. Angiology. 1969; 20(4):213-8. DOI: 10.1177/000331976902000405. View

CARLSTEN A, FOLKOW B, Grimby G, HAMBERGER C, Thulesius O . Cardiovascular effects of direct stimulation of the carotid sinus nerve in man. Acta Physiol Scand. 1958; 44(2):138-45. DOI: 10.1111/j.1748-1716.1958.tb01615.x. View

Heusser K, Tank J, Brinkmann J, Menne J, Kaufeld J, Linnenweber-Held S . Acute Response to Unilateral Unipolar Electrical Carotid Sinus Stimulation in Patients With Resistant Arterial Hypertension. Hypertension. 2016; 67(3):585-91. PMC: 4773922. DOI: 10.1161/HYPERTENSIONAHA.115.06486. View

Illig K, Levy M, Sanchez L, Trachiotis G, Shanley C, Irwin E . An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006; 44(6):1213-1218. DOI: 10.1016/j.jvs.2006.08.024. View

Paton J, Sobotka P, Fudim M, Engelman Z, Engleman Z, Hart E . The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. Hypertension. 2012; 61(1):5-13. DOI: 10.1161/HYPERTENSIONAHA.111.00064. View

Hoppe U, Brandt M, Wachter R, Beige J, Rump L, Kroon A . Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012; 6(4):270-6. DOI: 10.1016/j.jash.2012.04.004. View

Iturriaga R . Carotid Body Ablation: a New Target to Address Central Autonomic Dysfunction. Curr Hypertens Rep. 2018; 20(6):53. DOI: 10.1007/s11906-018-0849-z. View

10.

BILGUTAY A, Lillehei C . TREATMENT OF HYPERTENSION WITH AN IMPLANTABLE ELECTRONIC DEVICE. JAMA. 1965; 191:649-53. DOI: 10.1001/jama.1965.03080080039010. View

11.

Wallbach M, Born E, Kampfer D, Luders S, Muller G, Wachter R . Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system. Clin Res Cardiol. 2019; 109(4):513-522. DOI: 10.1007/s00392-019-01536-5. View

12.

DiBona G . The sympathetic nervous system and hypertension: recent developments. Hypertension. 2004; 43(2):147-50. DOI: 10.1161/01.HYP.0000113047.47711.fa. View

13.

Wallbach M, Lehnig L, Schroer C, Hasenfuss G, Muller G, Wachter R . Impact of baroreflex activation therapy on renal function--a pilot study. Am J Nephrol. 2014; 40(4):371-80. DOI: 10.1159/000368723. View

14.

Zile M, Abraham W, Lindenfeld J, Weaver F, Zannad F, Graves T . First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. Am Heart J. 2018; 204:139-150. DOI: 10.1016/j.ahj.2018.07.011. View

15.

Tordoir J, Scheffers I, Schmidli J, Savolainen H, Liebeskind U, Hansky B . An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg. 2007; 33(4):414-21. DOI: 10.1016/j.ejvs.2006.11.025. View

16.

Weaver F, Abraham W, Little W, Butter C, Ducharme A, Halbach M . Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. Semin Thorac Cardiovasc Surg. 2017; 28(2):320-328. DOI: 10.1053/j.semtcvs.2016.04.017. View

17.

Townsend R . Pathogenesis of drug-resistant hypertension. Semin Nephrol. 2014; 34(5):506-13. DOI: 10.1016/j.semnephrol.2014.08.004. View

18.

McBryde F, Hart E, Ramchandra R, Paton J . Evaluating the carotid bodies and renal nerves as therapeutic targets for hypertension. Auton Neurosci. 2016; 204:126-130. DOI: 10.1016/j.autneu.2016.08.002. View

19.

Calhoun D, Jones D, Textor S, Goff D, Murphy T, Toto R . Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008; 117(25):e510-26. DOI: 10.1161/CIRCULATIONAHA.108.189141. View

20.

Scheffers I, Kroon A, Schmidli J, Jordan J, Tordoir J, Mohaupt M . Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010; 56(15):1254-8. DOI: 10.1016/j.jacc.2010.03.089. View